| Oct 17 |
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
|
| Oct 17 |
Theratechnologies Unveils Study Design of PROMISE-US Trial of Ibalizumab
|
| Oct 17 |
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
|
| Oct 11 |
Theratechnologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Oct 11 |
Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ...
|
| Oct 10 |
Theratechnologies Up 12% in U.S. Premarket Trading After Reporting Q3 Swing to Profit
|
| Oct 10 |
Theratechnologies: Fiscal Q3 Earnings Snapshot
|
| Oct 10 |
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
|
| Oct 9 |
Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV
|
| Oct 9 |
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
|
